Publications

Filter by:

A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors

By:

Drew W. Rasco, MD, Manish R. Sharma, MD, Midwest, San Antonio, United States

Journal: Invest New Drugs

Published Date: March 14, 2024

A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors

By:

Amita Patnaik, MD, FRCPC, Manish R. Sharma, MD, Midwest, San Antonio, United States

Journal: Clin Ther.

Published Date: February 23, 2024

A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (PODIUM-101)

By:

Drew W. Rasco, MD, Midwest, Nehal Lakhani, MD, PhD, San Antonio, United States

Journal: ESMO Open

Published Date: February 21, 2024

First-in-human study with preclinical data of Bcl-2/Bcl-XL inhibitor Pelcitoclax in locally advanced or metastatic solid tumors

By:

Drew W. Rasco, MD, Midwest, Nehal Lakhani, MD, PhD, San Antonio, United States

Journal: Clinical Cancer Research

Published Date: February 1, 2024

Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug-Drug Interaction Study

By:

Barcelona, Emiliano Calvo, MD, PhD, Europe, Irene Moreno, MD, Madrid - CIOCC, Spain, Tatiana Hernández, MD

Journal: Pharmaceuticals

Published Date: January 30, 2024

Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts)

By:

Andrew L. Sochacki, MD, Midwest, United States

Journal: Blood

Published Date: November 28, 2023

A First-in-Human Phase 1 Study of ABBV-525, a Small-Molecule MALT1 Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

By:

Andrew L. Sochacki, MD, Midwest, United States

Journal: Blood

Published Date: November 28, 2023

Histology-agnostic drugs: A paradigm shift – A narrative review

By:

André Mansinho, MD, MSc

Journal: Advances in Therapy

Published Date: November 23, 2023

Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)

By:

Irene Moreno, MD

Journal: Clin Cancer Res.

Published Date: November 1, 2023

Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes

By:

Daniel Morillo, MD

Journal: Leuk Res

Published Date: September 20, 2023